

## Jeffrey C. Bank

PARTNER

Antitrust and  
Competition  
Washington, D.C.

jbank@wsgr.com  
212-497-7761



### FOCUS AREAS

Antitrust Civil Enforcement  
Antitrust Compliance and  
Business Strategy  
Antitrust Criminal  
Enforcement  
Antitrust Litigation  
Antitrust and Competition  
Antitrust and Intellectual  
Property  
Federal Trade Commission  
Third-Party Merger and  
Non-Merger Antitrust  
Representation

### HIGHLIGHTS

#### A Strategic Partner

Jeff serves as a strategic partner to clients in their most significant matters, identifying cost-effective strategies to secure favorable outcomes.

#### Key Industry Experience

Jeff has represented companies in antitrust litigation and counseling matters, particularly those in the pharmaceutical, healthcare, technology, manufacturing, and media industries.

#### A Recognized Practitioner

Jeff was recognized as a 2020 “Rising Star” in antitrust by *Law360*, in *Bloomberg Law’s* inaugural “40 Under 40” in 2021, and as a “Future Leader” in 2021-2024 and a 2024 “Global Elite Thought Leader” by *Global Competition Review/Who’s Who*.

### EXPERIENCE

Jeff Bank is a partner and co-chair of the antitrust litigation group at Wilson Sonsini Goodrich & Rosati. Jeff currently serves as a member of the firm’s Board of Directors.

As a seasoned litigator representing both plaintiffs and defendants, Jeff has handled a wide range of complex matters, from multi-district litigations and global cartel cases to actions against competitors. He has successfully defended pharmaceutical, technology, manufacturing, and media companies against class actions and has extensive experience in all aspects of litigation, from discovery through appeal. In the 2022 edition of *Who’s Who Legal - Competition*, Jeff was recognized as a “thoughtful and strategic litigator” who holds a “very strong client-orientated service.”

In addition to his litigation practice, Jeff regularly advises clients on business practices, government investigations, and merger clearance issues, and has represented a broad array of clients before federal and state agencies.

Jeff has successfully guided clients on all types of competition matters, including those related to monopolization, price-fixing, AI tools and pricing algorithms, exclusive dealing, and unfair competition. Jeff has also advised companies in a wide variety of industries and jurisdictions on compliance-related issues and has helped develop cutting-edge compliance programs for global and domestic entities. In addition, Jeff helps clients identify cost-effective strategies to overcome anticompetitive practices by competitors, and he has recovered hundreds of millions of dollars and regulatory relief on behalf of those clients.

Prior to joining the firm, Jeff practiced at the Federal Trade Commission’s Health Care Division, where he focused on competition issues in the pharmaceutical and healthcare industry.

Beyond his antitrust practice, Jeff is deeply committed to pro bono work. He currently serves on the firm's Pro Bono Committee and has worked on numerous immigration and asylum matters. He was honored with the John Wilson Award, which is presented annually to individual attorneys who have demonstrated a significant commitment to the firm's pro bono clients. Jeff is also the board president of Spoons Across America, a New York-based nonprofit.

## CREDENTIALS

---

### Education

- J.D., Cornell Law School, 2006  
*Editor*, International Law Journal
- B.S., Cornell University, School of Industrial and Labor Relations, 2003

### Honors

- Named a "Stand-out Lawyer" by *Thomson Reuters* in 2025
- Named among *Washingtonian's* 2024 Top Lawyers
- Named a "Future Leader" in 2021-2024 and a 2024 "Global Elite Thought Leader" by *Global Competition Review/Who's Who Legal: Competition*

### Admissions

- Bar of the District of Columbia
- State Bar of New York
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
- U.S. Court of Appeals for the First Circuit
- U.S. Court of Appeals for the Third Circuit
- U.S. Court of Appeals for the Ninth Circuit

## MATTERS

---

### Representative Matters

- Defending Mylan Inc. against price-fixing and market allocation claims in one of the largest multi-district litigations, *In re Generic Pharmaceuticals*, brought by private class and non-class plaintiffs as well as dozens of State AGs.
- Defending multi-family apartment owner/operator in *In re RealPage*, cutting-edge litigation brought by putative class of renters regarding algorithmic pricing software.
- Defending former CEO of healthcare company in alleged no-poach case brought by putative class of employees, *In re Outpatient*.
- Defending specialty pharmaceutical manufacturer in alleged sham litigation matter brought by generic competitor.
- Defending electronic technology company against California unfair competition claim brought by competitor.
- Defending global tire manufacturer against price-fixing claims brought by putative classes of purchasers in *In re Replacement Tires*.
- Defending news agency company against collusion claims.
- Representing pharmaceutical manufacturers in connection with reverse payment litigations, and obtained dismissals in other such litigations.
- Successfully resolved price-fixing claims against Hitachi Chemical in *In re Capacitors*.
- Represented cable network company in dispute with big data vendor.
- Successfully obtained millions of dollars and favorable resolutions for plaintiffs in monopolization claims against competitors, including on behalf of Mylan Pharmaceuticals, Amphastar Pharmaceuticals, and others.
- Developed and advised on compliance programs for various companies, including global development and construction company, spirits manufacturer and trade association, real estate company, watch manufacturer, electronic component manufacturer, and numerous pharmaceutical companies.
- Defeated class certification on behalf of Transitions Optical in *In re Photochromic Lens*.
- Successfully resolved antitrust claims against Walgreens in *Thompson v. 1-800 Contacts*.
- Obtained summary judgment for Netflix in *Resnick v. Netflix*.

## INSIGHTS

---

### Select Publications

- Co-author, “Enforcement Priorities of President Trump’s DOJ and FTC Begin to Take Shape,” Wilson Sonsini Alert, February 26, 2025
- Co-author, “Navigating Pharmaceutical Patent Settlements and Reverse Payments: Key Takeaways from the FTC’s Latest MMA Reports,” Wilson Sonsini Alert, January 22, 2025
- Co-author, “2025 Year in Preview: Trends and Key Decisions in Private Litigation,” Wilson Sonsini Alert, January 16, 2025
- Co-author, “The Fine Print of Competition: The Use of Jury Instructions in Labor-Related Cases to Modify the Standard of Proof,” 8(4) *Competition Law and Policy Debate*, 2024
- Co-author, “Latest Ruling Relating to Pricing Software Highlights Antitrust Risks,” Wilson Sonsini Alert, December 9, 2024
- Co-author, “Antitrust and Labor Issues Around the World: A Comparative Analysis,” American Bar Association’s *Antitrust Magazine*, Summer 2022
- Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, “Seventh Circuit Affirms Denial of Claims Brought Against AbbVie,” Wilson Sonsini Alert, August 8, 2022
- Co-author with N. Mendelsohn, K. O’Rourke, and J. Soven, “Ninth Circuit Limits Ability of Indirect Purchaser Classes to Bring Nationwide Suits,” Wilson Sonsini Alert, October 12, 2021
- Co-author with S. Chung and J. Jacobson, “Second Circuit Upholds Settlement Agreements Among Competitors Not to Bid on Rivals’ Names as Keywords,” Wilson Sonsini Alert, June 14, 2021
- Co-author with B. Coffman, R. Gray, N. Mendelsohn, and S. Silber, “Fifth Circuit Upholds Federal Trade Commission Ruling in Impax Laboratories, Inc. v. Federal Trade Commission and Grants Substantial Deference to the FTC,” Wilson Sonsini Alert, April 20, 2021
- Co-author with M. Rosman and B. Tuyay, “Retaining Ephemeral Messages To Prepare For DOJ Scrutiny,” *Law360*, July 29, 2019
- Co-author with C. Boylu and B. Coffman, “The Latest Developments in Antitrust Class Certification,” *Law360*, January 30, 2019
- “U.S.A.” chapter, *Competition Litigation 2018*, Tenth Edition, International Comparative Legal Guide, September 4, 2017
- “U.S.A.” chapter, *Competition Litigation 2017*, Ninth Edition, International Comparative Legal Guide, September 16, 2016
- Co-author with S. Silber and B. Coffman, “A Return to Republican Antitrust Policies for Pharma,” *Law360*, January 24, 2017
- Co-author with S. Silber, C. Armour, K. Kemp, B. Coffman, and R. Maddock, “Pharmaceutical Antitrust Litigation in 2015—Settlements, Product Hopping and REMS,” *CPI Antitrust Chronicle*, Competition Policy International, December 14, 2015
- Co-author with S. Silber, B. Coffman, and K. Kemp, “Where We Stand On Pharmaceutical Patent Settlements,” *Law360*, October 23, 2015
- “U.S.A.” chapter, *Competition Litigation 2016*, Eighth Edition, International Comparative Legal Guide, September 25, 2015
- Co-author with M. Rosman, S. Silber, J. VanHooreweghe, and B. Coffman, “DOJ Investigation into Generic Pharma: You Could Be Next,” *Law360*, March 30, 2015

## Select Speaking Engagements

- Panelist, “Challenges in Litigating Civil Cases with Parallel Criminal Investigation,” ABA Cartel and Criminal Practice Panel, June 2021
- Panelist, “Generics Exclusion: What Conduct Crosses the Lines?” Antitrust in Life Sciences Conference hosted by Concurrences and Fordham Competition Law Institute, July 2020
- Moderator, “Competition Enforcement of Digital Platforms in the US, Japan and Other Jurisdictions,” New York State Bar Association, Global Conference 2019, Tokyo, Japan
- Presenter, “Recent Developments in Private Litigation,” ABA Corporate Counseling Committee Monthly Antitrust Update, Section of Antitrust Law, February 2019
- “All Things Vertical: Divergence or Convergence?” Fordham Competition Law Institute 45th Annual Conference on International Antitrust Law and Policy, September 2018
- “REMS: Are the Federal Agencies Signaling Increased Scrutiny?” American Bar Association Health Care and Pharmaceuticals Committee Panel, June 2018
- “End the Shenanigans or Business as Usual?: Update on Pharmaceutical Antitrust Issues,” New York City Bar Association Antitrust & Trade Regulation Committee, November 2017
- “Pushing Forward or Staying the Course?: Product Hopping, Exclusionary Conduct, and the Recent Suboxone MTD Ruling,” American Bar Association State Enforcement Committee Panel, October 2017